Biosimilars for Rheumatoid Arthritis Will Experience Rapid Uptake in the Public Sectors of Brazil and Mexico, Which Have Powerful Mechanisms that Drive Use of Lower Cost Options In Brazil, Biosimilars from PDPs (Productive Development Partnerships) Will Have Significant Market Advantages, According to a New Report from Decision Resources
BURLINGTON, Mass., Dec. 18, 2013 /PRNewswire/-- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that biosimilars will be quickly acquired and used in public health institutions in Brazil and Mexico in the treatment of patients with rheumatoid arthritis (RA). Public formularies, treatment guidelines, public tender acquisition processes and prescriptions all reference only the molecular name of drugs in this sector in Brazil and Mexico, allowing for automatic integration of biosimilars with the same molecular name as currently covered branded biologics. Public tender, in particular, forces acquisition of the lowest-priced version of a drug, regardless of rheumatologist preferences.
The special report titled The Biosimilar Opportunity in Brazil and Mexico: How to Succeed and Thrive—Payer and Rheumatologist Perspectives finds that the current government in Brazil is investing in the national production of biosimilars to reduce the significant cost of imported, branded biologics for RA.
"Viable opportunities for Productive Development Partnerships (PDPs) to produce biosimilars in Brazil still exist and impart many benefits in the public sector market," said Decision Resources Director Andreia Ribeiro, Ph.D. "In fact, competing with PDP biosimilars in the public sector will be difficult upon their availability."
In addition, Brazil offers two approval pathways for non-original biologics: the individual development pathway and the comparability pathway. Approval via the comparability pathway for a PDP biosimilar will likely allow for exportation to other countries. Several PDPs that are developing biosimilars for RA have already determined that they will file through this pathway.
Biosimilars are not yet available in Brazil. In Mexico, three copy biologics are already prescribed in public institutions for RA, according to interviewed payers and surveyed rheumatologists. Most surveyed rheumatologists in both countries prefer branded biologics, and they can influence their continued use in the private sector. Physician preference for branded drugs will likely continue in the private setting, where private HMOs make direct purchases from manufacturers. Once biosimilars are available, the prices of the original brands of biologics are expected to drop to compete, and private insurance will likely be the only means for patients to access original brands.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
SOURCE Decision Resources